Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.

Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S.

Br J Cancer. 2010 Sep 28;103(7):1025-33. doi: 10.1038/sj.bjc.6605846. Epub 2010 Aug 31.

2.

Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S.

Int J Cancer. 2012 Sep 1;131(5):1169-78. doi: 10.1002/ijc.26495. Epub 2011 Nov 19.

3.

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.

Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S.

Int J Cancer. 2010 Jun 15;126(12):2863-73. doi: 10.1002/ijc.24908.

4.

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.

Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S.

Cancer. 2011 Apr 1;117(7):1399-408. doi: 10.1002/cncr.25630. Epub 2010 Nov 8.

5.

Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.

Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S.

Eur J Cancer. 2012 Dec;48(18):3405-13. doi: 10.1016/j.ejca.2012.06.021. Epub 2012 Jul 26.

6.

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Apr 15;18(8):2257-68. doi: 10.1158/1078-0432.CCR-11-2410. Epub 2012 Feb 22.

7.

Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer.

Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ, Oh SY, Kim MC, Kim KH, Kim SJ.

Oncology. 2013;85(2):78-85. doi: 10.1159/000351234. Epub 2013 Jul 16.

PMID:
23860205
8.

SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.

Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S, Qian ZR.

Ann Surg Oncol. 2014 Dec;21(13):4164-73. doi: 10.1245/s10434-014-3888-y. Epub 2014 Jul 15.

9.

Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.

Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC, Fuchs CS, Wu K, Chan AT, Zhang X, Ogino S, Qian ZR.

Br J Cancer. 2016 Jan 19;114(2):199-206. doi: 10.1038/bjc.2015.347. Epub 2016 Jan 7.

10.

Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S.

Clin Cancer Res. 2009 Jul 15;15(14):4665-73. doi: 10.1158/1078-0432.CCR-09-0401. Epub 2009 Jul 7.

11.

Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.

Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S.

JAMA. 2011 Apr 27;305(16):1685-94. doi: 10.1001/jama.2011.513.

12.

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

N Engl J Med. 2012 Oct 25;367(17):1596-606. doi: 10.1056/NEJMoa1207756.

13.

STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, Ogino S.

Clin Cancer Res. 2011 Mar 15;17(6):1452-62. doi: 10.1158/1078-0432.CCR-10-2694. Epub 2011 Feb 10.

14.

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS.

J Clin Oncol. 2009 Mar 20;27(9):1477-84. doi: 10.1200/JCO.2008.18.6544. Epub 2009 Feb 23.

15.

Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.

Hum Pathol. 2007 Jun;38(6):842-9. Epub 2007 Mar 12.

PMID:
17350669
16.

Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis.

Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS.

Gastroenterology. 2009 Apr;136(4):1242-50. doi: 10.1053/j.gastro.2008.12.048. Epub 2008 Dec 24.

17.

Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability.

Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS.

Arch Pathol Lab Med. 2008 Jun;132(6):958-64. doi: 10.1043/1543-2165(2008)132[958:CCCIMP]2.0.CO;2.

PMID:
18517279
18.

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.

Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia L, Lonardi S, Indraccolo S, Zagonel V.

Br J Cancer. 2014 Jul 8;111(1):25-32. doi: 10.1038/bjc.2014.274. Epub 2014 Jun 3.

19.

A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis.

Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM, Chan AT, Giovannucci EL, Fuchs CS.

Am J Gastroenterol. 2009 Aug;104(8):2047-56. doi: 10.1038/ajg.2009.281. Epub 2009 Jun 9.

20.

Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.

Georgieva M, Krasteva M, Angelova E, Ralchev K, Dimitrov V, Bozhimirov S, Georgieva E, Berger MR.

Oncol Rep. 2008 Jul;20(1):3-11.

PMID:
18575712

Supplemental Content

Support Center